Maggie Liu supports the pharmaceutical industry collaborative activity that attempts to find solutions to predict, prevent, and treat a rare, but life-threatening brain disease –a side effect associated with a variety of immunosuppressive therapies. She is a member of the Government and Regulatory Affair group’s Pharmaceutical team.
Maggie also supports an organization of pharmaceutical and biotechnology companies with a common goal to advance quality and innovation in the development of pharmaceutical products through scientifically driven best practices and standards.
She has published research articles in prestigious scientific journals such as Nature, Proceedings of the National Academy of Sciences, and Trends in Immunology. Maggie is a native speaker of Mandarin Chinese.
- Yale University, Ph.D., Biomedical Sciences/Immunology, 2008
- Peking University - P.R. China, B.S., 2002, summa cum laude